FDA clears first blood-based Alzheimer’s check (BIIB:NASDAQ)

The Meals and Drug Administration (FDA) has cleared Lumipulse G for U.S. commercialization as the primary blood-based check that might assist in the prognosis of Alzheimer’s illness.

Developed by Pennsylvania-based Fujirebio Diagnostics, Lumipulse G acquired the FDA’s 510 ((ok)) clearance on Friday